Perry Nisen

Chief Executive Officer

2021

RAS has the highest frequency of mutation of any oncogene in human cancer. Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types. Our team applies deep biologic insight, unique protein conformation detection technology and sophisticated medicinal chemistry expertise to develop novel small molecules as first-in-class precision medicines breaking the resistance paradigms of targeted therapy in oncology.

Executive Partner

2018

I joined Sofinnova as Executive Partner in 2018. I am a physician scientist with extensive experience in drug discovery and development, focusing on later stage pre-clinical and clinical companies with particular interest in oncology, neuroscience and immunology/inflammation.

Independent Director, Chair of Science and Technology

2017

Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. Teva is committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, Teva has significant innovative research and operations supporting a growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Chief Executive Officer, Donald Bren Chief Executive Chair

2014 - 2017

As CEO of the Sanford Burnham Prebys Medical Discovery Institute (SBP), I was responsible for all aspects of the organization including strategy, operations and performance.

SVP Science and Innovation

2012 - 2014

I held multiple senior leadership positions during my tenure at GlaxoSmithKline (GSK) including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head. As Oncology Therapy Area Head, I was accountable for the Oncology portfolio from target to market. Responsibilities at GSK included all aspects of drug discovery, clinical development, risk/benefit and operations

Interim Chief Medical Officer

2012 - 2012

Senior Vice President and Therapeutic Area Head, Oncology Research and Development

2010 - 2012

SVP Cancer Research

2008 - 2010

SVP Clinical Pharmacology and Discovery Medicine

2004 - 2008

Division VP Global Oncology Development

2001 - 2004

Division VP Cancer Research

1997 - 2001

Professor

1997 - 1997

I was the Lowe Foundation Professor of Neurooncology. I was an attending physician pediatric hematologist-oncologist, led an NIH funded molecular biology research laboratory focused on oncology, and held training and program project grants

Associate Professor

1992 - 1997

Member, Genetics and Development Graduate Training Program

1989 - 1997

Assistant Professor

1989 - 1992